Following the resistance pattern of mycobacterium tuberculosis
(naslov ne postoji na srpskom)
Shurbeska Boneva Biljanaa, Nikolovska Jasminab, Mitrevski Vladimira, Zejnel Seada, Chamurovski Nikolaa, Merdžanovski Ersina, Savin Ivanovska Biljanaa, Aleksovska Gjuzelova Aleksandaa, Jorganovikj Stojkoska Aleksandraa, Bikova Gjurgjicaa, Sandevski Aleksandara, Filipce Milchoa, Nanović Zoricac, Metodieva Marijaa, Pilovska Karolinaa, Tushevska Mitkovska Monikaa
aInstitute for lung diseases and tuberculosis, Skopje, North Macedonia
bCenter for Public Health Bitola, Bitola, North Macedonia
cInstitute for lung diseases and tuberculosis, Skopje, North Macedonia + Goce Delcev University, Štip, North Macedonia
Sažetak
(ne postoji na srpskom)
Background: Tuberculosis (TB) accounts for over 40% of all mortality cases from communicable diseases in Europe.Multidrug-resistant TB (MDR-TB) is TB that does not respond to at least isoniazid and rifampicin, the 2 most powerful anti-TB drugs. 30 countries worldwide are classified as high multi drug resistant (MDR) TB burden countries, nine are in the European Region. The emergence of combined resistance to rifampicin and isoniazid (MDR-TB) is a matter of global concern. Methods and Objectives: Over a period of 10 years we examined patient specimens for TB. Culture-positive samples were subjected to identification, and those cultures identified as M. tuberculosis (MTB) complex were subjected to drug susceptibility testing (DST). DST for first-line drugs was performed using proportional method on Lowenstein Jensen, and in recent years, rapid molecular techniques recommended by WHO (GeneXpert). DST for second line drugs was assessed using Geno Type MTBDRsl. Results: In the period 2012-2022 we tested 1554 TB strains, 1449 (93,24%) were found to be sensitive and 99 (6,37%) resistant to first-line drugs. 75 strains (4,83%) were monoresistant, 15 (0,96%) of which were resistant only to Rifampicin. Of the total 1423 strains, 22 (1,41%) were found to be MDR. Conclusions: Currently a low 1,41% of our isolates are MDR. It is necessary to strengthen our TB laboratory capacity for early detection of drug-resistant TB. This is best done by using rapid molecular diagnosis as an initial method for all cases with clinical suspicion of TB.
|